Free Trial

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 9.3% - Should You Buy?

Eyepoint Pharmaceuticals logo with Medical background

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report)'s stock price rose 9.3% during trading on Tuesday . The stock traded as high as $9.01 and last traded at $9.05. Approximately 267,876 shares were traded during trading, a decline of 67% from the average daily volume of 813,070 shares. The stock had previously closed at $8.28.

Analyst Ratings Changes

EYPT has been the subject of several recent research reports. HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, May 29th. Wall Street Zen raised shares of Eyepoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Royal Bank Of Canada started coverage on Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 target price for the company. Chardan Capital cut their target price on Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Finally, Mizuho reduced their price target on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, May 16th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $25.67.

Check Out Our Latest Stock Analysis on Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals Stock Down 7.0%

The firm has a market cap of $663.33 million, a P/E ratio of -4.00 and a beta of 1.61. The business's 50 day moving average is $7.27 and its two-hundred day moving average is $6.96.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting the consensus estimate of ($0.65). The firm had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. Eyepoint Pharmaceuticals had a negative return on equity of 54.27% and a negative net margin of 261.91%. Equities research analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in EYPT. California State Teachers Retirement System grew its position in shares of Eyepoint Pharmaceuticals by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after buying an additional 1,797 shares during the period. Arizona State Retirement System boosted its stake in Eyepoint Pharmaceuticals by 12.7% during the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock worth $90,000 after acquiring an additional 1,877 shares in the last quarter. Legal & General Group Plc boosted its stake in Eyepoint Pharmaceuticals by 4.4% during the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock worth $345,000 after acquiring an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in Eyepoint Pharmaceuticals by 39.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after purchasing an additional 1,940 shares during the period. Finally, Invesco Ltd. boosted its holdings in Eyepoint Pharmaceuticals by 16.1% in the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company's stock worth $117,000 after acquiring an additional 2,177 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

(Get Free Report)

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

See Also

Should You Invest $1,000 in Eyepoint Pharmaceuticals Right Now?

Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.

While Eyepoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines